Jemperli (dostarlimab-gxly) Approved in US as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer

Oct 20, 2026 - 00:00
 0  0
Philadelphia, PA -- October 19 2026 -- GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) as the first and only immunotherapy for adults with stage II and III microsatellite...

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0